Clinical Trial Update: A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FCR001 to standard of care in de novo living donor kidney transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection
• Transplanted Organ Rejection

Drugs mentioned

• FCR001

Snippet

Sponsor: Talaris Therapeutics Inc. | Conditions: Transplanted Organ Rejection | Phase 3 | Status: TERMINATED